https://mindmedicinelaw.com/briefing/evolving-drug-detection-strategies-forensic-and-clinical-impacts-20260803-28905The Psychedelic Journalen2026-08-04T15:07:11.159539+00:00Evolving Drug Detection Strategies: Forensic and Clinical Impactsdrug detection methods, new psychoactive substances, forensic applications, clinical settings, chromatographic methods, mass spectrometry, electrochemical platforms, biosensor technologies, field screening, public health monitoringhttps://mindmedicinelaw.com/briefing/mechanisms-of-psychedelic-therapy-new-approaches-explored-20260803-28904The Psychedelic Journalen2026-08-04T15:06:53.233459+00:00Mechanisms of Psychedelic Therapy: New Approaches Exploredpsychedelic therapy, low-dose psychedelics, breathwork, vagus nerve stimulation, serotonergic neurochemistry, psychiatric conditions, clinical trials, neurochemical plasticity, autonomic recalibration, tailored interventionshttps://mindmedicinelaw.com/briefing/5-meo-dmt-cbt-in-alcohol-use-disorder-uk-trial-insights-20260803-28934The Psychedelic Journalen2026-08-04T15:06:41.650403+00:005-MeO-DMT & CBT in Alcohol Use Disorder: UK Trial Insights5-MeO-DMT, cognitive behavioral therapy, alcohol use disorder, psychedelic-assisted therapy, psychological change, clinical trial, addiction treatment, emotional regulation, self-awareness, London UKhttps://mindmedicinelaw.com/briefing/fda-revises-guidance-on-tds-for-andas-implications-for-psychedelics-20260803-28632The Psychedelic Journalen2026-08-03T15:06:14.347459+00:00FDA Revises Guidance on TDS for ANDAs: Implications for PsychedelicsFDA guidance, transdermal delivery systems, ANDAs, psychedelic compounds, skin irritation studies, drug approval process, in vivo studies, sensitization potential, drug delivery safety, psychedelic researchhttps://mindmedicinelaw.com/briefing/dea-s-expanded-listing-for-pmk-glycidic-acid-implications-20260803-28604The Psychedelic Journalen2026-08-03T15:06:00.405231+00:00DEA's Expanded Listing for PMK Glycidic Acid: ImplicationsDEA, PMK glycidic acid, list I chemicals, MDMA synthesis, chemical regulation, research compliance, Controlled Substances Act, chemical manufacturing, drug enforcement, precursor chemicalshttps://mindmedicinelaw.com/briefing/psychological-control-reserve-model-implications-for-therapy-20260802-28935The Psychedelic Journalen2026-08-04T15:07:20.703470+00:00Psychological Control & Reserve Model: Implications for Therapypsychological control, psychological reserve, psychotherapy, psychedelic-assisted therapy, cognitive control, emotional regulation, therapeutic frameworks, psychological resiliencehttps://mindmedicinelaw.com/briefing/pilot-study-on-aspirin-ketamine-for-knee-pain-management-20260801-28689The Psychedelic Journalen2026-08-03T15:06:25.728489+00:00Pilot Study on Aspirin & Ketamine for Knee Pain Managementaspirin, ketamine, pain management, knee surgery, clinical trials, postoperative care, multimodal pain relief, opioid alternatives, NMDA receptor antagonist, acute painhttps://mindmedicinelaw.com/briefing/htr2a-gene-s-role-in-psychedelic-effects-and-research-20260801-28514The Psychedelic Journalen2026-08-02T22:05:09.425941+00:00HTR2A Gene's Role in Psychedelic Effects and ResearchHTR2A gene, psychedelic effects, cortical changes, serotonin receptor, therapeutic applications, transcriptomic studies, neural cell cultures, Allen Human Brain Atlas, mental health treatment, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/new-model-for-estimating-e-i-balance-via-m-eeg-20260731-28515The Psychedelic Journalen2026-08-02T22:05:24.021452+00:00New Model for Estimating E/I Balance via M/EEGexcitation inhibition balance, M/EEG recordings, schizophrenia research, psychiatric disorders, synaptopathy, personalized interventions, neuroscience, clinical trials, brain function, psychedelic researchhttps://mindmedicinelaw.com/briefing/magnesium-s-impact-on-cortical-neuron-dynamics-new-insights-20260730-28519The Psychedelic Journalen2026-08-02T22:05:31.685172+00:00Magnesium's Impact on Cortical Neuron Dynamics: New Insightsmagnesium, neuronal dynamics, burstiness, NMDA receptors, neurological disorders, cortical cultures, information processing, brain health, therapeutic applications, neuroscience researchhttps://mindmedicinelaw.com/briefing/us-psilocybin-legalization-state-efforts-and-global-impact-20260730-28487The Psychedelic Journalen2026-08-02T22:05:16.185161+00:00US Psilocybin Legalization: State Efforts and Global Impactpsilocybin legalization, US policy, state initiatives, psychedelic research, global model, activism, investment, therapeutic use, legal framework, federal roadblockshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-for-racial-trauma-a-new-study-in-jamaica-20260730-28484The Psychedelic Journalen2026-08-02T22:05:01.031100+00:00Psychedelic Therapy for Racial Trauma: A New Study in Jamaicapsychedelic therapy, racial trauma, cultural safety, community affirmation, psilocybin, neuroplasticity, mental health, race-based traumatic stress, culturally responsive care, Healing Racial Trauma Protocolhttps://mindmedicinelaw.com/briefing/advancements-in-ketamine-analysis-hair-testing-breakthrough-20260729-28955The Psychedelic Journalen2026-08-04T15:07:29.805465+00:00Advancements in Ketamine Analysis: Hair Testing Breakthroughketamine analysis, hair testing, enzyme immunoassay, LC-MS/MS, clinical trials, forensic investigations, drug monitoring, compliance tracking, research methods, drug detectionhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-pediatric-anesthesia-new-findings-20260728-27857The Psychedelic Journalen2026-08-02T22:05:38.684057+00:00Esketamine's Role in Pediatric Anesthesia: New Findingsesketamine, pediatric anesthesia, limb withdrawal, rocuronium, anesthesia protocols, dose-dependent effects, Hangzhou Children's Hospital, adverse reactions, patient safety, clinical trialshttps://mindmedicinelaw.com/briefing/standardizing-integration-in-psychedelic-therapy-trials-20260726-28929The Psychedelic Journalen2026-08-04T15:07:02.050189+00:00Standardizing Integration in Psychedelic Therapy Trialspsychedelic-assisted therapy, integration practices, clinical trials, standardized protocols, psilocybin, participant safety, therapist qualifications, cross-trial comparisons, mental health treatment, phase III trialshttps://mindmedicinelaw.com/briefing/evaluating-glycyrrhiza-glabra-s-anxiolytic-potential-20260725-27693The Psychedelic Journalen2026-08-03T15:06:40.203327+00:00Evaluating Glycyrrhiza glabra's Anxiolytic Potentialglycyrrhiza glabra, anxiolytic effects, canrenoic acid, natural therapeutics, anxiety treatment, clinical trials, pharmacological evaluation, CNS modulation, mental health, phytochemical profilinghttps://mindmedicinelaw.com/briefing/synergistic-effects-of-dds-and-nac-in-spinal-cord-injury-pain-20260723-27697The Psychedelic Journalen2026-08-03T15:06:55.922059+00:00Synergistic Effects of DDS and NAC in Spinal Cord Injury Paindapsone, N-acetylcysteine, neuropathic pain, spinal cord injury, oxidative stress, preclinical study, synergistic effects, pain management, clinical trials, antioxidant therapyhttps://mindmedicinelaw.com/briefing/tmem16a-inhibition-and-stroke-implications-for-therapy-20260722-27703The Psychedelic Journalen2026-08-03T22:05:40.307725+00:00TMEM16A Inhibition and Stroke: Implications for TherapyTMEM16A inhibition, cerebral autoregulation, stroke therapy, vascular mural cells, Ca²⁺-activated Cl⁻ channels, ischemia-reperfusion injury, targeted stroke treatment, cerebral perfusion, vascular research, stroke recoveryhttps://mindmedicinelaw.com/briefing/chemsex-patterns-in-msm-sex-workers-vs-content-creators-20260722-27701The Psychedelic Journalen2026-08-03T15:07:07.673993+00:00Chemsex Patterns in MSM Sex Workers vs. Content Creatorschemsex, MSM sex workers, digital content creators, harm reduction, public health, psychoactive substances, occupational context, substance use patterns, clinical outreach, tailored interventions